Expression of multidrug resistance (MDR)-associated proteins in solid tumors;Expresión de proteínas relacionadas con resistencia a múltiples fármacos (MDR-proteínas) en tumores sólidos

Cirugia Espanola

Volumn 79, Issue 4, 2006, Pages 202-214

  Paredes, Alfredo ^a   Blanco, José Luis ^a   Echenique Elizondo, Miguel ^b  

^a HOSPITAL DONOSTIA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Proteins; Solid tumors; Tumors

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

BIOSYNTHESIS; DRUG RESISTANCE; HUMAN; METABOLISM; NEOPLASM; REVIEW;

DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS;

EID: 33745913932     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(06)70855-7     Document Type: Review

References (139)

1. Beck WT, Dalton WS. Mechanisms of drug resistance. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 5th ed. Philadelphia: JB Lippincont; 1997. p. 498-512.
2. Chu E, DeVita VT. Principles of cancer management: chemotherapy. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 6th ed. Philadelphia: JB Lippincont; 2001. p. 289-386.
3. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XII: on the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chem Rep. 1964;35:1.
4. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer treat Rep. 1979;631727-31.
5. Skipper HE, Simpson-Herren L. Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. En: DeVita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: JB Lippincont; 1985. p. 63-77.
6. Nishio K, Nakamura T, Koh Y, et al. Drug resístance in lung cancer. Curr Opin Oncol. 1999;11:109-15.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-14.
8. Carney DN, Shepherd FA. Treatment of SCLC: chemotherapy. En: Hansen HH, editor. Textbook of lung cancer. London: Martín Dunitz; 2000. p. 261-72.
9. Shepherd FA, Carney DN. Treatment of NSCLC: chemotherapy. En: Hansen HH, editor. Textbook of lung cancer. London: Martín Dunitz; 2000. p. 213-42.
10. Doyle LA. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol. 1993;20:326-37.
11. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-20.
12. Koomagi R, Mattern J, Volm M. Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res. 1999;19:4333-6.
13. Bradshaw D, Arceci RJ. Clinical Relevance of Transmembrane Drug Efflux as a Mechanism of Multidrug Resistance. J Clin Oncol. 1998;16:3674-90.
14. Duchesne MG. Fundamental bases of combined therapy in lung cancer: cell resitance to chemotherapy and radiotherapy. Lung Cancer. 1994;10 Suppl 1:S67-S72.
15. Dalton WS. Overcoming the Multidrug-Resistant Phenotype. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. Philadelphia: JB Lippincont Company; 1993. p. 2655-66.
16. Simon MF, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 1994;91:3497-504.
17. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12:450-8.
18. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol. 2001;2:33-42.
19. Morrow ChS, Cowan KH. Mechanisms of antineoplastic drug resistance. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 4th ed. Philadelphia: JB Lippincont Company; 1993. p. 340-8.
20. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diammine- dicloroplatinum (II). Metabolism and ATP-depedent efflux from leukemia cells. J Biol Chem. 1993;268:20116-25.
21. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-302.
22. Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small-cell lung carcinomas of smokers. Br J Cancer. 1991;64:700-4.
23. Kreisholt J, Sorensen M, Jensen PB, et al. Inmunohistochemical detection of DNA topoisomerasa IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer. 1998;77:1469-73.
24. Plasencia C, Tarón M, Abad A, et al. Genes de quimiorresistencia. En: Rosell R, Abad A, Monzó M, Barnadas A, editores. Manual de oncología clínica y molecular. Madrid: Arán Ediciones; 2000. p. 145-59.
25. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-cell lung cancer. Ann Oncol. 1999;10 Suppl 5:S83-6.
26. Drake FH, Hofmann GA, Bartus HF, et al. Bichemical and Pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989;28:8154-60.
27. Stewart CF, Ratain MJ. Topoisomerase interactive agents. En: De-Vita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 6th ed. Philadelphia: JB Lippincont Company; 2001. p. 415-31.
28. Giaccone G, Van Ark-Otte J, Scagliotti G, et al. Differential expression of DNA topoisomerases in non-small-cell lung cancer and normal lung. Biochim Biophys Acta. 1995;1264:337-46.
29. Dingemans AC, Van Ark-Otte J, Span S, et al: Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer. 2001;32:117-28.
30. Rosell R, Monzo M, Alberola V, et al. Determinants of response and resístance to cytotoxics. Semin Oncol. 2002;29 Suppl 4:110-8.
31. Yang HH, Ma MH, Vescio RA, et al. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21:4239-47.
32. Leonard CJ, Canman CE, Kastan MB. The role of p53 in cell-cycle control and apoptosis: implications for cancer. En: DeVita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: JB Lippincont-Raven; 1995. p. 33.
33. Marie JP. Drug resistance in hematologic malignances. Curr Opin Oncol. 2001;13:463-9.
34. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;2:459-62.
35. Harada T, Ogura S, Yamakazi K, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Science. 2003;94:394-9.
36. Kawasaki M, Nakanishi Y, Kuwano K, et al. Inmunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998;34:1352-7.
37. Galimberti S, Marchetti A, Buttitta F, et al. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res. 1998;18:2973-6.
38. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001;19:448-57.
39. nd, et al. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-samall cell lung cancer. Cancer Invest. 2002;20:686-92.
40. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild- type p53. Cancer Res. 1998;58:5762-9.
41. Smyth M, Krasovskis E, Sutton V, et al. The drug efflux protein, Pglycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA. 1988;95:7024-9.
42. Solary E, Droin N, Bettaieb A, et al. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematologycal malignances. Leukemia. 2000;14:1833-49.
43. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of atp-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
44. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascitis tumor cells. Biochim Biophys Acta. 1973;323:466-83.
45. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-62.
46. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221:1285-8.
47. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650-4.
48. Cordón-Cardo C, O'Brian JP. El fenotipo de resistencia a múltiples fármacos en el cáncer humano. En: DeVita VT, Hellman S, Rosenberg SA, editores. Avances en oncología 1991 (ed. esp.). Barcelona: Espaxs; 1992. p. 35-55.
49. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989;81:116-24.
50. Zaman GJR, Flens MJ, Van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 1994;91:8822-6.
51. Koomagi R, Stammler G, Manegold C, et al. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett. 1996;110:129-36.
52. Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst. 1999;91:1647-53.
53. Scheffer GL, Wijngaard PLJ, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nature Med. 1995;1:578-82.
54. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000;95:2897-904
55. Lincke CR, Smitt JJ, Van der Velde-Koerts T, et al. Structure of the Human MDR3 Gene and Physical Mapping of the Human MDR Locus. J Biol Chem. 1991;266:5303-10.
56. De Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA. 1998;95:282-7.
57. Scheffer GL, Pijnenborg ACLM, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol. 2002;55:332-9.
58. Sugawara I, Akiyama S, Scheper RJ, et al. Lung resistance protein (LRP) expression in human normal tissues comparison with that of MDR1 and MRP. Cancer Lett. 1997;112:23-31.
59. Godstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer. 1996;32A:1039-50.
60. Trock B, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analisys of MDR1/Gp170 expression and its possible functional significace. J Natl Cancer Inst. 1997;89:917-31.
61. Ng I, Lam K, Ng M, et al. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer. 1998;83:851-7
62. Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994;54:4833-6.
63. Rappa G, Loico A, Flavell R, et al. Evidence that the multidrug resitance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 1997;57:5232-7.
64. Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357-61.
65. Young LC, Campling BG, Voskolou-Nomikos T, et al. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res. 1999;5:673-80.
66. Thomas GA, Barrand MA, Stewart S, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer. 1994;30:1705-9.
67. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med. 1998;157:S210-3.
68. Young LC, Campling BG, Cole SPC, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7:1798-804.
69. Oguri T, Isobe T, Fujitaka K, et al. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer. 2001;93:584-9.
70. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr 110.000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475-9.
71. Slovak ML, Pelkey Ho J, Cole SPC, et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on cromosoma 16: evidence that chromosoma breakage plays a key role in MRP or LRP gene amplification. Cancer Res. 1995;55:4214-9.
72. Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol. 1986;103:699-709.
73. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci. 1993;106:23-9.
74. Dingemans AMC, Van Ark-Otte J, Van der Valk P, et al. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol. 1996;7:625-30
75. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol. 1996;148:877-87
76. Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotipes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer. 1996;65:230-7.
77. Ikeda K, Oka M, Narasaki F, et al. Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells. Anticancer Res. 1998;18:3077-80.
78. Allikmets R, Schriml L, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosoma 4q22 that is involved in multidrug resistance. Cancer Res. 1998,58:5337-9.
79. Miyake K, Mickley L, Litman T, et el. Molecular cloning of cDNA which are highly overexpress in mitoxantrone-resistant cells: demostration of homology to ABC transport genes. Cancer Res. 1999;59:8-13.
80. Ross D, Yang W, Abruzzo L, et al. Atipycal multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999;91:429-33.
81. Maliepaard M, Van Gastelen MA, De Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan selected ovarian tumor cell line. Cancer Res. 1999;59:4559-63.
82. Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 1999;96:365-8.
83. Kawabata S, Oka M, Soda H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003;9:3052-7.
84. Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 2002;8:1068-74.
85. Broxterman HJ, Lankelma J, Pinedo HM, et al. How to probe clinical tumour samples for P-glycoprotein and multidrug resistanceassociated protein. Eur J Cancer. 1996;32A:1024-33.
86. Campling BG, Young LC, Baer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res. 1997;3:115-22.
87. Duhem C, Ries F, Dicato M. What does multidrug resistance (MDR) expression mean in the clinic? The Oncologist. 1996;1:151-8.
88. Twentyman PR. MDR1 (P-glycoprotein) gene expression. Implications for resistance modifier trials. J Natl Cancer Inst. 1992;84:1458-60.
89. Sonneveld P. Multidrug resistance in hematological malignancies. J Intern Med. 2000;247:521-34.
90. Baumforth KNR, Nelson PN, Digby JE, et al. The polymerase chain reaction. J Clin Pathol Mol Pathol. 1999;52:1-10.
91. Giaccone G, Van Ark-Otte J, Rubio GJ, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer. 1996;66:760-7.
92. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumours: consensus recomendations. Cancer Res. 1996;56:3010-20.
93. Scagliotti GV, Michelotto F, Kalikatzaros G, et al. Detection of multidrug resistance associated P-170 glycoprotein in previously untreated non small cell lung cancer. Anticancer Res. 1991;11:2207-10.
94. Wright S, Boag A, Valdimarsson G, et al. Inmunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Cancer Res. 1998,4:2279-89.
95. Xu M, Li J, Xia Q. Expression of multidrug resistance-associated protein gene in non-small cell lung cancer. Zhonghua Yi Xue Za Zhi. 1999;22:268-70.
96. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 2003;10:159-65.
97. 99mTc- sestamibi is a substrate for P-glycoprotein and the multidrug resistance associated protein. Br J Cancer. 1998;77:353-8.
98. 99mTc-sestamibi scintimammography predicts response to neoadyuvant chemotherapy and is related to MDR expression. Int J Oncol. 2002;20:1049-55.
99. 99mtechnetium-methoxyisobutylisonitrile with histologycal necrosis following induction chemotherpy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res. 2001;7:3065-70.
100. Kostakoglu L, Kiratli P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228-34.
101. Kao A, Shiun SC, Hsu NY, et al. Technetium-99m metoxyisobutilisonitrile chest imaging for small cell lung cancer: Relatioship to chemotherpy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol. 2001;12:1516-66.
102. Zhou J, Higashi K, Ueda Y, et al. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer. J Nucl Med. 2001;42:1476-83.
103. Kao CH, Changlai SP, Chieng PU, et al. Technetium-99m Methoxyisobutylisonitrile Chest Imaging of Small Cell Lung Carcinoma. Cancer. 1998;83:64-8.
104. Shiau Y, Tsai S, Wang J, et al. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett. 2001;169:181-8.
105. Dirlik A, Burak Z, Goksel T, et al. The role of Tc-99m sestamibi imaging in predicting clinical respose to chemotherapy in lung cancer. Ann Nucl Med. 2002;16:103-8.
106. Shi D, Huang G, Miao J, et al. Correlationof the uptake of technetium-99 methoxyisobutyl isonitrilo with expression of multidrug resistance genes mdr-1 and MRP in human lung cancer. Zhonghua Yi Xue Za Zhi. 2002;82:824-7.
107. Kuo TH, Liu FY, Chuang CY. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression. Nuclear Med Biol. 2002;30:627-32.
108. Bates SE, Chen C, Robey R, et al. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Foundation Symposium. 2002;243:83-102.
109. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991;83:105-10.
110. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug resistant myeloma: Laboratory and clinical effects of Verapamil as a chemosensitizer. Blood. 1991;78:44-50.
111. Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in pacientes with refractory myeloma. A South-West Oncology Group study. Cancer. 1995;75:815-20.
112. Wattel E, Solary E, Hecquet B, et al. Quinina improves the results of intensive chemotheraphy in myelodysplastic syndromes expressing P-glycoprotein: results of a randomized study. Br J Haematol. 1998;102:1015-24.
113. Milroy R. A randomized clinical study of verapamil in addition to combination chemotherapy in small-cell lung cancer. Br J Cancer. 1993;68:813-8.
114. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst. 2000;92:898-902.
115. Baer MR, George SL, Dodge RK, et al. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 Years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224-32.
116. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with bricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998;16:2964-76.
117. Dantzig AH, Law KL, Cao J, et al. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem. 2001;8:39-50.
118. Petrylack DP, Sher HI, Reuter V, et al. Expresión de P-glicoproteína en el carcinoma de células transicionales de vejiga primario y metástasico. Ann Oncol (ed. esp.). 1995;1:68-74.
119. Tada Y, Wada M, Migata T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorrubicin. Int J Cancer. 2002;98:630-5.
120. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst. 1994;86:1539-45.
121. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol. 1997;15:3249-57.
122. Sinicrope FA, Hart J, Brasitus TA, et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994;74:2908-17.
123. Benchimol S, Ling V. P-glycoprotein and tumor progression. J Natl Cancer Inst. 1994;86:814-6
124. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991;325:1608-14.
125. Chan HSL, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990;8:689-704.
126. Schneider J, González-Roces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of recue mastectomy after induction chemotherapy. Breast Cancer Res. 2001;3:183-91.
127. Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171-6.
128. Warmann S, Hunger M, Teichmann B, et al. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer. 2002;95:1795-801.
129. Hsu CH, Chen CL, Hong RL, et al. Prognostic value of multidrug resistance 1, gltathione-s-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology. 2002;62:305-12.
130. Chan HS, Lu Y, Grogan TM, et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 1997;57:2325-30.
131. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of Pglycoprotein in hiah grade osteosarcoma in relation to dlinical out come. N Engl J Med. 1995;333:1380-5.
132. Cheson BD. Miscellaneous chemotherapeutic agents. En: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 6th ed. Philadelphia: JB Lippincont; 2001. p. 452-9.
133. Choi JH, Lim HY, Joo HJ, et al. Expression of multidrug resistance-associated protein 1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adyuvant chemotherapy after curative resection. Br J Cancer. 2002;86:1578-85.
134. Oudard S, Levalois C, Andrieu JM, et al. Expression of genes involved in chemoresistence, proloferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical ourcome. Anticancer Res. 2002;22:121-8.
135. Arts HJG, Katsaros D, De Vries EGE, et al. Drug Resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res. 1999;5:2798-805.
136. Nakayama K, Kanzaki A, Ogawa K, et al. Copper-transporting P-type adenosine triphosphate (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer. 2002;101:488-95.
137. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2000;18:2685-94.
138. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistence related transporters in human breast cancer. Jpn J Cancer Res. 2001;92:452-8
139. Soini Y, Järvinen K, Kaarteenaho-Wiik R, et al. The expression of P-glycoptotein and multidrug resistence protein 1 and 2 (MRP1 and MRP2) in human makignant mesothelioma. Ann Oncol. 2001;12:1239-45.